197 related articles for article (PubMed ID: 31125365)
1. Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand.
Karunasinghe N; Symes E; Gamage A; Wang A; Murray P; Zhu S; Goudie M; Masters J; Ferguson LR
PLoS One; 2019; 14(5):e0217373. PubMed ID: 31125365
[TBL] [Abstract][Full Text] [Related]
2. Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts.
Karunasinghe N; Ambs S; Wang A; Tang W; Zhu S; Dorsey TH; Goudie M; Masters JG; Ferguson LR
PLoS One; 2018; 13(6):e0199122. PubMed ID: 29920533
[TBL] [Abstract][Full Text] [Related]
3. Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?
Karunasinghe N; Zhu Y; Han DY; Lange K; Zhu S; Wang A; Ellett S; Masters J; Goudie M; Keogh J; Benjamin B; Holmes M; Ferguson LR
BMC Urol; 2016 Aug; 16(1):48. PubMed ID: 27485119
[TBL] [Abstract][Full Text] [Related]
4. Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions.
Karunasinghe N; Minas TZ; Bao BY; Lee A; Wang A; Zhu S; Masters J; Goudie M; Huang SP; Jenkins FJ; Ferguson LR
Sci Rep; 2022 Jan; 12(1):55. PubMed ID: 34997089
[TBL] [Abstract][Full Text] [Related]
5. Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review.
Karunasinghe N; Masters J; Flanagan JU; Ferguson LR
Curr Cancer Drug Targets; 2017; 17(7):603-616. PubMed ID: 28359237
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Park S; Song CS; Lin CL; Jiang S; Osmulski PA; Wang CM; Marck BT; Matsumoto AM; Morrissey C; Gaczynska ME; Chen Y; Mostaghel EA; Chatterjee B
Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31894239
[TBL] [Abstract][Full Text] [Related]
7. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.
Tian Y; Zhao L; Zhang H; Liu X; Zhao L; Zhao X; Li Y; Li J
Diagn Pathol; 2014 Feb; 9():42. PubMed ID: 24571686
[TBL] [Abstract][Full Text] [Related]
8. Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.
Voon PJ; Yap HL; Ma CY; Lu F; Wong AL; Sapari NS; Soong R; Soh TI; Goh BC; Lee HS; Lee SC
Br J Clin Pharmacol; 2013 Jun; 75(6):1497-505. PubMed ID: 23116553
[TBL] [Abstract][Full Text] [Related]
9. 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer.
Barnard M; Quanson JL; Mostaghel E; Pretorius E; Snoep JL; Storbeck KH
J Steroid Biochem Mol Biol; 2018 Oct; 183():192-201. PubMed ID: 29936123
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Sun SQ; Gu X; Gao XS; Li Y; Yu H; Xiong W; Yu H; Wang W; Li Y; Teng Y; Zhou D
Oncotarget; 2016 Jul; 7(30):48050-48058. PubMed ID: 27385003
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
Byrns MC; Mindnich R; Duan L; Penning TM
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
[TBL] [Abstract][Full Text] [Related]
13. Influence of aldo-keto reductase 1C3 polymorphisms in early-onset female psoriasis patients.
Nojiri Y; Nakamura M; Magara T; Yamamoto A; Ikumi K; Nakamura R; Nishida E; Haarmann-Stemmann T; Morita A
Sci Rep; 2023 Feb; 13(1):3280. PubMed ID: 36841845
[TBL] [Abstract][Full Text] [Related]
14. Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor.
Morsy A; Trippier PC
ACS Chem Biol; 2020 Mar; 15(3):646-650. PubMed ID: 32125151
[TBL] [Abstract][Full Text] [Related]
15. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
[TBL] [Abstract][Full Text] [Related]
16. Transition from androgenic to neurosteroidal action of 5α-androstane-3α, 17β-diol through the type A γ-aminobutyric acid receptor in prostate cancer progression.
Xia D; Lai DV; Wu W; Webb ZD; Yang Q; Zhao L; Yu Z; Thorpe JE; Disch BC; Ihnat MA; Jayaraman M; Dhanasekaran DN; Stratton KL; Cookson MS; Fung KM; Lin HK
J Steroid Biochem Mol Biol; 2018 Apr; 178():89-98. PubMed ID: 29155210
[TBL] [Abstract][Full Text] [Related]
17. The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
Fan L; Peng G; Hussain A; Fazli L; Guns E; Gleave M; Qi J
J Biol Chem; 2015 Aug; 290(34):20865-20879. PubMed ID: 26160177
[TBL] [Abstract][Full Text] [Related]
18. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.
Tian Y; Zhao L; Wang Y; Zhang H; Xu D; Zhao X; Li Y; Li J
Asian J Androl; 2016; 18(4):607-12. PubMed ID: 26698234
[TBL] [Abstract][Full Text] [Related]
19. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
[TBL] [Abstract][Full Text] [Related]
20. Association of AKR1C3 Polymorphisms with Bladder Cancer.
Tiryakioglu NO; Tunali NE
Urol J; 2016 Apr; 13(2):2615-21. PubMed ID: 27085562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
